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Abstract
Background: There is concern that untreated individuals in mass drug administration (MDA) programs for neglected
tropical diseases can reduce the impact of elimination efforts by maintaining a source of transmission and re-infection.
Methodology/Principal Findings: Treatment receipt was recorded against the community census during three MDAs with
azithromycin for trachoma in The Gambia, a hypo-endemic setting. Predictors of non-participation were investigated in 1–9
year olds using random effects logistic regression of cross-sectional data for each MDA. Two types of non-participators were
identified: present during MDA but not treated (PNT) and eligible for treatment but absent during MDA (EBA). PNT and EBA
children were compared to treated children separately. Multivariable models were developed using baseline data and
validated using year one and two data, with a priori adjustment for previous treatment status. Analyses included
approximately 10000 children at baseline and 5000 children subsequently. There was strong evidence of spatial
heterogeneity, and persistent non-participation within households and individuals. By year two, non-participation increased
significantly to 10.4% overall from 6.2% at baseline, with more, smaller geographical clusters of non-participating
households. Multivariable models suggested household level predictors of non-participation (increased time to water and
household head non-participation for both PNT and EBA; increased household size for PNT status only; non-inclusion in a
previous trachoma examination survey and younger age for EBA only). Enhanced coverage efforts did not decrease non-
participation. Few infected children were detected at year three and only one infected child was EBA previously. Infected
children were in communities close to untreated endemic areas with higher rates of EBA non-participation during MDA.
Conclusions/Significance: In hypo-endemic settings, with good coverage and no association between non-participation
and infection, efforts to improve participation during MDA may not be required. Further research could investigate spatial
hotspots of infection and non-participation in other low and medium prevalence settings before allocating resources to
increase participation.
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Introduction
Trachoma is a leading cause of preventable blindness in
endemic areas [1]. Control is through the SAFE strategy [2], of
which a key component is mass drug administration (MDA)
with the antibiotic azithromycin. Entire communities are
targeted during MDA in order to reach both pre-school and
school aged children who form the reservoir of infection for
Chlamydia trachomatis, the causative bacterial agent for
trachoma [3].
There is renewed commitment from the World Health
Organization (WHO), donors of funding for disease control and
research and also pharmaceutical companies to support efforts to
eliminate Neglected Tropical Diseases (NTDs), including tracho-
ma, by 2020 [4–6]. The success of MDA for NTDs is thought to
depend heavily on adequate population coverage in affected areas
and participation amongst those offered treatment [7,8]. With
increasing provision of MDA for trachoma, prevalence is expected
to fall so that endemic areas will, over time, become low
prevalence settings on a trajectory towards the endgame of
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elimination [4]. In such settings, MDA participation amongst
those at highest risk of infection is important. If spatial clusters, or
hotspots, of non-participation occur during MDA and correlate
with hotspots of infection, it is possible that reservoirs of infection
could remain to facilitate continued transmission [9]. This would
in turn increase the time needed to reach elimination goals.
Identification of factors associated with persistent non-participa-
tion in low prevalence settings could therefore provide important
clues about how to minimise non-participation. Determining
whether infected individuals are amongst non-participators in
previous annual MDAs may also provide information regarding
the importance of non-participation in low prevalence areas and
the potential need for resources to improve participation.
C. trachomatis infection, follicular trachoma (TF) and non-
participation with azithromycin MDA have all been found to
cluster within communities and also within households [10–16].
Limited data on non-participation in trachoma control suggest
that non-participation is associated mainly with household level
decision-making factors, related to knowledge and awareness of
trachoma control and also mode of delivery (for example,
perception of community drug distributors). A case-control study
in Tanzania found household level risk factors such as guardians of
children reporting better health in themselves, increased burden
due to poor family health, more children per household and
younger guardians [3]. At community level, enhanced effort to
increase coverage during implementation of MDA was successful
in achieving higher participation rates. Studies in Nigeria and
South Sudan identified prior household head knowledge of
trachoma control and prior notification of MDA as factors
associated with better participation but no association with age or
gender [17,18]. In a cluster randomised trial (CRT) in Ethiopia,
women and younger children were more likely to be non-
participators [15].
For CRTs evaluating the impact of MDA intervention, non-
participation can be problematic as it can reduce power to detect
intention-to-treat effects [19] and lead to bias in results if there is
systematic or heterogeneous non-participation due to reasons also
associated with the outcome [20,21].
In the Partnership for Rapid Elimination of Trachoma (PRET)
CRT in The Gambia [22,23] which represents a hypo-endemic
setting (prevalence of TF of 10–20%[7,24]), MDA took place over
a three year period to evaluate the effectiveness of different
frequency and coverage MDA delivery strategies on C. trachomatis
infection and TF in children aged 0–5 years. The aims of this
study are to quantify non-participation amongst children aged 1–9
years during PRET, to identify factors associated with non-
participation of different types at child, household and community
level, to investigate the presence of heterogeneity of non-
participation at household and, or community level and determine
if any observed household or community heterogeneity is spatially
clustered.
Methods
Ethical approval
Approval was obtained from the London School of Hygiene &
Tropical Medicine Ethics Committee, and The Gambia Govern-
ment/Medical Research Council Unit, The Gambia Joint Ethics
Committee. Written informed consent was obtained from a parent
or guardian prior to examination for all children.
Study design
In PRET, 48 communities (enumerations areas, or EAs) were
randomised in a 262 factorial design to MDA delivery strategies
[11,22,23]. A frequency strategy allocation resulted in either three
annual MDAs of all community members in 24 communities or
MDA at baseline only in the remaining 24 communities. A
coverage strategy allocation (24 communities per arm) was either
standard (one day visit to each community by the treatment team
of National Eye Health Program (NEHP) in The Gambia) or
enhanced (two visits to each community to achieve higher
coverage). At the end of the trial, the overall prevalence of TF
was around 3% and of C. trachomatis, less than 1%.
All community members in treated EAs were eligible to receive
azithromycin, with the exception of pregnant women and children
under six months old who were offered tetracycline ointment if
needed. The study took place in two adjacent districts on the
northern Bank of the River Gambia and two adjacent districts on
the southern Bank (Figure 1) identified for azithromycin MDA.
Figure 1. Location of the study districts within The Gambia.
Dark grey: study districts, pale grey: remaining districts of The Gambia.
doi:10.1371/journal.pntd.0003098.g001
Author Summary
As the target year for Global Elimination of Trachoma
(GET2020) approaches, the scale up of mass drug
administration (MDA) with azithromycin will lead to more
endemic areas becoming low prevalence settings. In such
areas, identification of those at highest risk of Chlamydia
trachomatis infection and at highest risk of non-participa-
tion during MDA could inform control planning, especially
if correlation is present. We investigated non-participation
in children aged 1–9 years during three annual MDAs in
The Gambia, a low prevalence setting. We found evidence
that non-participation is associated with household mem-
bership and decision-making, as seen in medium and high
prevalence settings in East Africa. In addition, we demon-
strate geographical heterogeneity (spatial clustering) of
non-participation, persistent non-participation behaviour
over time and different non-participator types. Between
the first and third MDA, non-participation increased
significantly overall from 6.2% to 10.4%, whilst spatial
clusters became smaller with non-participation more
focused in single households or small groups of house-
holds. There was no evidence of association between
infection and non-participation. In low prevalence settings
with no evidence to suggest non-participation as a risk
factor for infection, resources to improve participation may
not be required. Spatial hotspot analysis could address this
research question in areas with more infection.
Heterogeneous Non-Participation during Azithromycin Mass Treatment
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Twelve EAs per district were randomly selected so that only one
EA within settlements of more than one EA was chosen. A
restricted randomisation of EAs within districts to trial arms was
performed by the trial statistician, such that all EA within larger
settlements of multiple EA received the same allocation to avoid
contamination.
Every six months, between baseline and 36 months inclusive, a
complete census was taken. Following this, a random sample of
children aged 0–5 years was taken from each community in order
to measure trachoma outcomes (the primary outcomes of PRET;
presence of TF and C. trachomatis infection). Full details of survey
methods, sampling strategies and measurement of trachoma
outcomes are published elsewhere [11,22]. MDA took place
within approximately one month of the examination rounds.
Treatment receipt for each individual was recorded against the
census.
Treatment
A central treatment station was set up in each community
during MDAs. Adults aged 14 years or above received 1 g of
azithromycin and height was used as a surrogate for weight for
children’s dosing on the basis of 20 mg/kg [25]. Treatment was
administered and directly observed by NEHP treatment teams and
the number of tablets or ml of suspension recorded within pre-
printed fields included in census forms.
NEHP staff attended the initial training workshop for the PRET
trial. Prior to each MDA, treatment team leaders received training
about recording treatment status on census forms from the trial
coordinator and about dosing from NEHP. Team leaders trained
their team. Data review and feedback took place throughout
MDAs. Communities were sensitised to MDA by the trial field
team before fieldwork started. During the census prior to
treatment, the study was again explained to households, and the
expected dates for examination and treatment teams’ visits were
explained. Supervisory field visits were conducted by the NEHP to
ensure appropriate distribution. Treatment team members were
given per diems to cover food and accommodation for days spent
in the field, as a single payment at the end of the fieldwork based
on the expected number of days needed.
For each MDA, treatment receipt and eligibility were catego-
rised according to one of the following categories:
N Ineligible: not yet added to the cohort, deceased before MDA,
moved elsewhere
N Present not treated (PNT): eligible for treatment as a resident
in the census and slept in the household the night before the
MDA, but not presenting for treatment
N Treated
N Eligible for treatment but absent (EBA): eligible for treatment
as a resident in the census but absent on the treatment day (did
not sleep in the household the night before the treatment)
N Eligible for treatment but status unknown (EBU): treatment
status not recorded.
Outcomes and other data
Two binary outcomes were analysed for each MDA; 1) PNT
versus treated and 2) EBA versus treated.
EA level variables included coverage allocation, North or South
river bank and district, EA type (single settlement, multi-
settlement, or segment of a settlement) and population size (small:
,600, medium: 600–800, large: .800 individuals). For house-
holds, variables included size (small: ,11, medium: 11–16, large:
.16 individuals), latrine access, time to primary water source,
recall of community health education, years of education of
household head, a diagnosis of TF for a child aged 0–5 years in the
household during the survey immediately prior to the MDA and
treatment status of the household head. Child level variables were
gender, age, participation in a previous ocular examination survey
and treatment status at previous MDAs. Latitude and longitude
coordinates were measured for each household.
Analysis methods
Data were analysed using Stata, version 13 Special Edition [26]
and SaTScan [27] and mapped using Quantum GIS [28]. All EAs
were treated at baseline and 24 EAs at year one and year two. All
available data for children aged 1–9 at the time of each MDA in
treated EAs were used to analyse non-participation in this sub-
study of the PRET trial. Children with unknown (missing)
outcome data were excluded.
The number (%) of children treated, PNT or EBA was
summarised overall and by characteristics of interest for each
MDA, treating each as a cross-sectional survey (Table S1). Using
random effects logistic regression, multivariable models were
developed for both outcomes using the baseline data. EA level
random intercepts were included in all models and household level
random intercepts for EBA versus treated comparisons. PNT
children were too few to include a household level random effect.
Factors associated with the outcome by a likelihood ratio test
(LRT) p-value of ,0.1 in univariable analyses were included in a
step-wise model building approach to obtain a final multivariable
model. Coverage delivery allocation was included in all multivar-
iable models a priori since by design the enhanced allocation was
intended to increase participation. The same multivariable models
were fitted to the year one and two MDA data for validation.
Treatment status at previous treatment rounds was added to each
of these final models a priori. Tests for interaction with coverage
allocation were pre-specified if an association between coverage
allocation and the outcome was found. Intracluster correlation
coefficients (ICCs) with corresponding 95% confidence intervals
were obtained from final multivariable models.
Considering the study areas north and south of the River
Gambia separately, spatial point patterns were investigated using
Kulldorf’s scan statistic [29] for each MDA round (baseline, year
one and year two), in order to test whether PNT and EBA cases
were randomly distributed over space compared to treated
children and to identify the location of any significant spatial
clusters. Within SatScan software, a circular window is moved
systematically throughout the geographic space to identify clusters
by centring the window on each household location with a window
size of 0% to 50% of the study population, to allow detection of
small and large clusters. Clusters containing more than 50% of the
population are ignored. A LRT test for a Poisson based model was
conducted for each location and size of scanning window to test
the hypothesis of an increased rate of non-participator type
compared with the distribution outside the window. P-values
corresponding to the most likely and secondary clusters are
determined using Monte Carlo replications of the dataset. Spatial
clusters of PNT and EBA children were added to maps showing
the location of children and their treatment status. The locations of
infected children at year three are shown on the map for the year
two MDA for visual inspection.
Results
Treatment status was unknown for 403 (3.6%), 88 (1.6%) and
187 (3.0%) eligible children at baseline, year one and year two,
Heterogeneous Non-Participation during Azithromycin Mass Treatment
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respectively. Participation was high overall during each MDA.
The overall prevalence of non-participation at baseline was 6.2%
(604/9777) with 1.0% (99/9777) of children being PNT and 5.2%
(505/9777) of children EBA (Table S1). The distribution of
treatment status was similar at year one. Over the three MDAs,
the percentage of EBA children appeared to increase and the
percentage of PNT children to decrease. By year two, overall non-
participation increased to 10.4% (paired t-test of EA summary
data p,0.01) due to the increase in EBA children. Reductions in
PNT non-participation were not significant.
Of 1626 households eligible for treatment in 24 annually treated
communities, one household (0.1%) had PNT children in all three
Table 1. Baseline univariable analysis.
PNT vs Treateda N=9272 EBA vs Treatedb N=9678
Characteristic OR (95 CI) LRT p-valuec OR (95 CI) LRT p-valuec
Coverage Standard 1 1
Enhanced 0.93 (0.25–3.53) 0.916 0.58 (0.34–0.99) 0.051
Bank South 1 1
North 0.18 (0.04–0.85) 0.016 1.28 (0.74–2.22) 0.375
District South: District 1 1 1
South: District 2 9.43 (1.65–54.2) 0.002 0.52 (0.25–1.09) 0.288
North: District 1 0.33 (0.03–3.34) 0.86 (0.41–1.82)
North: District 2 1.62 (0.25–10.7) 1.00 (0.48–2.07)
EA type Multiple-SET 1 1
Multiple-EA 0.42 (0.10–1.84) 0.289 1.23 (0.66–2.28) 0.793
Single EA-SET 0.25 (0.03–2.02) 1.15 (0.51–2.59)
EA size Small 1 1
Medium 2.19 (0.43–11.3) 0.386 0.62 (0.33–1.18) 0.292
Large 3.23 (0.59–17.7) 0.65 (0.33–1.28)
HH size Small 1 1
Medium 0.43 (0.26–0.69) ,0.001 0.93 (0.67–1.30) 0.921
Large 0.22 (0.12–0.40) 0.97 (0.69–1.37)
Latrine access No 1 1
Yes 0.54 (0.26–1.10) 0.106 1.13 (0.69–1.85) 0.640
Time to water $15 mins 1 1
,15 mins 0.48 (0.28–0.80) 0.005 0.58 (0.38–0.87) 0.010
Recall of health education No 1 1
Yes 1.25 (0.71–2.23) 0.443 0.70 (0.50–0.98) 0.037
Years of education of head ,1 year 1 1
$1 year 1.31 (0.64–2.68) 0.472 0.91 (0.48–1.71) 0.764
Gender Male 1 1
Female 0.76 (0.50–1.15) 0.188 1.11 (0.90–1.37) 0.322
Age (years) 6–9 1 1
3–5 1.00 (0.62–1.61) 0.396 1.02 (0.80–1.30) ,0.001
1–2 1.39 (0.83–2.31) 1.65 (1.27–2.15)
TF diagnosis in HH prior to treatment No 1 1
Yes 0.39 (0.15–0.99) 0.025 0.94 (0.61–1.46) 0.786
Previous ocular exam Yes 1 1
No 1.46 (0.92–2.30) 0.101 2.85 (2.17–3.75) ,0.001
Household head treatment statusd Treated 1 1
PNT - ,0.001 1.42 (0.47–4.34) 0.001
EBA - 2.68 (1.68–4.29)
Untreated or EBU 3.85 (2.38–6.22) -
Ineligible or EBU - 0.85 (0.33–2.17)
aEA level random effect included in logistic regression model.
bEA and household (HH) random effects included in logistic regression model.
cLRT = likelihood ratio test of overall association, comparing models with and without characteristic of interest.
dre-grouping of categories necessary due to zero events in some categories.
doi:10.1371/journal.pntd.0003098.t001
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MDAs and 34 (2.1%) had EBA children in all three MDAs.
Persistent EBA households were generally larger and within EAs
comprised of multiple settlements. The persistent PNT household
was further from water, without latrine access and with a
household head with no recall of health education or education.
Univariable analyses of baseline data are presented in Table 1.
The final multivariable model for being PNT versus treated at
baseline included coverage allocation, time to water, household
size, household head treatment status and district (Table 2).
Children residing in a medium or large household compared to
small (p,0.001) and within 15 minutes of primary water source
(p,0.001) were less likely to be PNT. A child was more likely to be
PNT if the household head was untreated (p,0.001). An
association with district was also found (p = 0.002), due to a
difference between districts south of the River Gambia. No effect
of coverage allocation was found (p = 0.842). A TF diagnosis in the
household during the baseline examination round, approximately
one month prior to treatment, was associated with lower odds of
being PNT in univariable analyses (Table 1) but not after
adjustment for other factors in the final model.
The same final model was fitted to the year one and year two
data, adding previous treatment status. For these follow-up
MDAs, the fixed term for district was removed due to zero PNT
cases north of the river. Treatment status one year previously was
an important predictor of non-participation at both years one and
two, with children who were PNT at the previous round being
more likely to be PNT again the following year (baseline
treatment status at year one MDA: p = 0.034, year one treatment
status at year two MDA: p= 0.032, Table 2). Treatment status at
baseline was not associated with being PNT at year two
(p = 0.656).
The final multivariable model for being EBA versus treated at
baseline (Table 3) suggested being EBA was more likely for
children who were not included in the baseline examination round
(p,0.001), aged 3–5 or 1–2 years compared to 6–9 years (p,
0.001), whose household head was also EBA compared to treated,
Table 4. Spatial clusters of non-participation.
Type Clusters Radius (km) p-value
Baseline:
North River Bank
PNT 1 3.13 ,0.001
EBA 1 6.27 ,0.001
2 0.062 0.001
3 0.048 0.002
4 0 0.010
South River Bank
PNT 1 7.43 ,0.001
EBA 1 3.64 ,0.001
2 0.054 ,0.001
3 0 0.001
4 0.22 0.010
Year one:
North River Banka
EBA 1 0.85 ,0.001
South River Bank
PNT 1 4.80 ,0.001
EBA 1 0 ,0.001
2 0.12 0.001
Year two:
North River Banka
EBA 1 0.079 ,0.001
2 0.080 0.027
South River Bank
PNT 1 0 ,0.001
2 0 0.002
3 0 0.002
4 0 0.0002
EBA 1 0.25 ,0.001
2 0.026 0.001
3 0.35 0.013
ano PNT children at year one or year two in districts north of the River Gambia.
doi:10.1371/journal.pntd.0003098.t004
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who resided in households further from water (p = 0.018) and
possibly for those whose household head could not recall
community health education (p = 0.060). Coverage allocation
was not associated with being EBA (p= 0.166). Children who
were EBA at each previous round were more likely to be EBA at
later time points (Table 3). Results also suggest that children who
were ineligible at both previous treatment rounds were more likely
to be EBA at year two.
In the EBA versus treated comparisons ICCs suggested
substantially more variation was present between households
within EAs, than between EAs (Table 3). ICCs from PNT models
at EA level were closer to the ICCs estimated at household level
for EBA children, possibly because between-household variation
could not be determined due to the very low prevalence of PNT
non-participation.
GPS coordinates were missing for 11 out of 1626 households,
excluding 23 children from spatial analyses.
Spatial clusters of PNT and EBA children were detected at
baseline in study areas on each side of the river (Table 4). No PNT
children were reported in year one or year two in the northern
river bank districts. Spatial clusters of PNT and EBA children
reduced in size in each subsequent MDA and by year two, clusters
included either single households or a small group of adjacent
households (Figures 2 and 3).
Cases of C. trachomatis infection in annually treated commu-
nities at year three (n = 14) were found within three kilometres of
Senegal in all but one child. In Senegalese districts adjacent to
The Gambia, MDA had not yet taken place. Infections were
detected amongst children who were ineligible or treated during
the three prior MDAs, apart from one child residing on the north
side of the river who was persistently EBA during the MDAs.
Two cases were located in an EA with households within a year
two EBA cluster on the south side of the river (Figures 2 and 3).
In the two EAs with households in this spatial cluster,
approximately 15% of 1–9 year olds were EBA during the year
two MDA.
Discussion
In this large study of non-participation during azithromycin
MDA from a low prevalence trachoma setting, we demonstrate
further evidence of heterogeneity of non-participation in children
aged 1–9 years, particularly at household level, in line with studies
in higher prevalence settings. We also observed persistent non-
participation over time in annual MDAs, as seen elsewhere in a
CRT setting [3]. Geographical clustering of non-participation
represents a new finding and we found two different types of non-
participators. We found circumstantial rather than statistical
evidence of an association between infection and non-participation
during a previous MDA, however, the overall prevalence of
infection and TF in 0–5 year olds at the end of PRET was below a
level requiring any SAFE interventions. Detection of infection in
communities close to untreated areas [22], relatively high EBA
rates in those communities during the previous MDA and
literature from The Gambia and elsewhere linking travel with
re-infection [30,31] together, suggest the observed infections could
have resulted from exposure to untreated persons. Travel plans
could have been set prior to notification of MDA timing and
therefore could have been unrelated to intentional non-participa-
tion, although intentional decision making to miss treatment is a
possibility.
Household level variables were associated with greater likeli-
hood of being PNT and EBA. Household head non-participation
and their type of non-participation predicted PNT and EBA status
in children, implying household decision making with respect to
MDA participation behaviour. The finding that children in
households further from their primary water source were more
likely to be PNT or EBA is probably indicative of some other
unmeasured risk factor, for example, marginalisation within the
community due to either household head or community leader
choice, or a mixture of the two. Non-participation during MDA
subsequent to participation in a previous MDA has been found to
be associated with possible markers of marginalisation in another
CRT [32]. Active trachoma has been found to be associated with
Figure 2. Spatial clusters of PNT and EBA children aged 1–9
years on the North river bank. A: baseline treatment round, B: year
one, C: year two. Treated (grey), PNT (red), EBA (blue), PNT cluster (pink),
EBA cluster (light blue). No PNT children at year one or year two in study
districts north of the river. Location of children aged 0–5 years with C.
trachomatis infection at year three (green).
doi:10.1371/journal.pntd.0003098.g002
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lower socio-economic status (SES) and isolation of households
from the community [33] so access to, or participation in,
trachoma control activities could also be affected by these
unmeasured factors. Smaller household size was important for
predicting PNT status but not EBA, compared to treated children,
which could represent some effect of lower SES. Recent migration
into the community could also mean less access to community
decision making and activities. Participation in a previous TF
examination survey could be indicative of increased awareness and
acceptance of control activities in annually treated communities,
however, a proxy effect cannot be concluded in case of potential
bias introduced by households more willing to take part in all
control and assessment activities. Results from the Gambian
setting suggest that enhanced efforts to increase coverage of mass
Figure 3. Spatial clusters of PNT and EBA children aged 1–9 years on the South river bank. A: baseline treatment round, B: year one, C:
year two. Treated (grey), PNT (red), EBA (blue), PNT cluster (pink), EBA cluster (light blue). Location of children aged 0–5 years with C. trachomatis
infection at year three (green).
doi:10.1371/journal.pntd.0003098.g003
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treatment programs, by means of an extra treatment team visit to
the community do not improve participation, in contrast to the
PRET trial conducted in Tanzania [3].
Studies of MDA participation in Africa for onchocerciasis and
lymphatic filariasis, other NTDs for which control is through mass
community-wide treatment, have also linked non-participation to
household level decision making factors, for example, a perception
of low disease risk or lack of family or household support [34–36].
The Gambia has relatively high childhood immunisation coverage
[37], elimination of trachoma by 2020 is attainable [24] and non-
participation was higher in the districts south of the river where the
prevalence of TF was consistently lower during PRET [22]. It is
perhaps plausible therefore that a household level decision based
on a perceived lack of need for treatment could apply in this low
prevalence setting, although we do not have data from each
community to assess this. Reasons for being EBA in this setting
could be logistic and independent of participation choices, for
example, population movement and travel where children are sent
away for weaning which is common practice in The Gambia, or
farming related activities. PNT and EBA comparisons to treated
children were performed separately as it was hypothesised that there
may be differences in reasons for non-participation that may or may
not be related to refusal of treatment or a perceived lack of need for
treatment. The data do suggest some differences between PNT and
EBA children but further information is unavailable to determine if
and why there was an active decision to refuse treatment.
Due to the very low prevalence of TF and infection in both
MDA frequency arms (annual and baseline only MDA) through-
out the original trial, it is unlikely that the heterogeneous non-
participation observed here had an additional negative effect on
power to detect differences between arms in intention-to-treat
analyses in the PRET trial. It is also unlikely that heterogeneous
non-participation introduced bias in comparative analyses given
the low prevalence of TF and infection. We found a geographical
effect on non-participation and on trachoma outcomes [22].
Infections did occur in one part of the study area with notable
EBA non-participation at the previous MDA, however, even if all
PNT and EBA children at the year two MDA had been found to
have infection and TF, the overall prevalence of each outcome at
year three would have been less than 5% and thus still below
MDA continuation thresholds for TF. Therefore, for the Gambian
national trachoma control program, efforts and resources to
address non-participation are not required.
For national control programs in low and medium prevalence
settings, heterogeneous non-participation linked to increased risk
of infection could present challenges for elimination efforts. Links
between infection and non-participation in prior MDA rounds
could undermine MDA where corresponding prevalence levels for
TF meet criteria for continued MDA at the time of impact
assessment. Identification of hotspots of infection and non-
participation, along with modifiable risk factors for non-partici-
pation could take place during impact assessment following
repeated MDA. The results could then aid control program
managers working towards elimination goals in low and medium
prevalence settings, by enabling them to target delivery resources
for continued MDA and to improve coverage in areas with a
greater threat of continued transmission.
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